Lack of ROS1 gene rearrangement in glioblastoma multiforme

Sun Min Lim; Junjeong Choi; Jong Hee Chang; Jinyoung Sohn; Kristine Jacobson; Frank Policht; John Schulz; Byoung Chul Cho; Se Hoon Kim

doi:10.1371/journal.pone.0137678

Lack of ROS1 gene rearrangement in glioblastoma multiforme

Sun Min Lim, Junjeong Choi, Jong Hee Chang, Jinyoung Sohn, Kristine Jacobson, Frank Policht, John Schulz, Byoung Chul Cho, Se Hoon Kim

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O⁶-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

Original language	English
Article number	e0137678
Journal	PloS one
Volume	10
Issue number	9
DOIs	https://doi.org/10.1371/journal.pone.0137678
Publication status	Published - 2015 Sep 14

Bibliographical note

Funding Information:
This study was funded in part by Novartis Pharmaceuticals. Jinyoung Sohn is employed by JEUK Co., Ltd. John Schulz is employed by Abbott Molecular Diagnostics. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Publisher Copyright:
© 2015 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

General

Access to Document

10.1371/journal.pone.0137678

Cite this

@article{ffd80317a7ed4a6c938f32721f95a098,

title = "Lack of ROS1 gene rearrangement in glioblastoma multiforme",

abstract = "Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.",

author = "Lim, {Sun Min} and Junjeong Choi and Chang, {Jong Hee} and Jinyoung Sohn and Kristine Jacobson and Frank Policht and John Schulz and Cho, {Byoung Chul} and Kim, {Se Hoon}",

note = "Funding Information: This study was funded in part by Novartis Pharmaceuticals. Jinyoung Sohn is employed by JEUK Co., Ltd. John Schulz is employed by Abbott Molecular Diagnostics. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Publisher Copyright: {\textcopyright} 2015 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2015",

month = sep,

day = "14",

doi = "10.1371/journal.pone.0137678",

language = "English",

volume = "10",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "9",

}

TY - JOUR

T1 - Lack of ROS1 gene rearrangement in glioblastoma multiforme

AU - Lim, Sun Min

AU - Choi, Junjeong

AU - Chang, Jong Hee

AU - Sohn, Jinyoung

AU - Jacobson, Kristine

AU - Policht, Frank

AU - Schulz, John

AU - Cho, Byoung Chul

AU - Kim, Se Hoon

N1 - Funding Information: This study was funded in part by Novartis Pharmaceuticals. Jinyoung Sohn is employed by JEUK Co., Ltd. John Schulz is employed by Abbott Molecular Diagnostics. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Publisher Copyright: © 2015 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

AB - Glioblastoma multiforme (GBM) is the most aggressive type of brain tumor, and the prognosis remains poor. Rearrangement of ROS1 gene, which was shown to have an oncogenic potential, was previously discovered in GBM cell lines. In this pilot study, we aimed to identify the incidence of ROS1 rearrangement in GBM patient tissues to explore novel biomarkers for therapeutic strategy. Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 109 patients with GBM were screened for ROS1 rearrangement by anti-ROS immunohistochemistry (IHC) and ROS1 break-apart fluorescent in situ hybridization (FISH) assays. O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and Isocitrate dehydrogenase 1 (IDH1) mutation status were also assessed. All samples were interpreted by two experienced pathologists who were blinded to the clinical data. A total of 109 samples were collected and all samples were examined for ROS1 rearrangement by IHC and FISH assays, and none was found to harbor ROS1 rearrangement. MGMT gene methylation was found in 42 (39.2%) cases, and IDH1 mutation was found in 6 (5.5%) cases. In this study, ROS1 rearrangement was not identified in GBM patients, and thus it is difficult to classify ROS1 rearrangement as a novel molecular subset in GBM patients for now.

UR - http://www.scopus.com/inward/record.url?scp=84947447625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947447625&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0137678

DO - 10.1371/journal.pone.0137678

M3 - Article

C2 - 26366867

AN - SCOPUS:84947447625

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0137678

ER -

Lack of ROS1 gene rearrangement in glioblastoma multiforme

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this